Specialities

Specialities

Artificial Intelligence
Anterior Segment
Cataract Surgery
Corneal and External Disorders
COVID-19
Diabetic Macular Oedema
Diabetic Retinopathy
Glaucoma
Imaging
Macular Degeneration
Neuro-ophthalmology
Ocular Oncology
Ocular Surface Disease
Oculoplastic Surgery
Paediatric Ophthalmology
Refractive Surgery
Retina/Vitreous
Ocular Immunology
Posterior Segment
Search

Trending Topic
23 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Noninfectious Uveitis: A Review of Ophthalmic Management and Clinical Pearls

Luke G Qin, Michael T Pierce, Rachel C Robbins

The uvea is a vascular stratum that includes the iris, ciliary body and choroid. Uveitis is defined as inflammation of a part of the uvea or its entirety, but it is also used to describe inflammatory processes of any part of the eye, such as the vitreous or peripheral retina. The clinical taxonomy of uveitis […]

touchREVIEWS in Ophthalmology. 2024;19(1):1–8:Online ahead of journal publication

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
Retina/Vitreous
2 mins

Beyond Anti-VEGFs – Anti-Insulin Receptor Substrate-1 Oligonucleotides as a Novel Approach to Ocular Neovascular Disorders

James W Bainbridge, Vanya Loroch, Eric Viaud, Claus Cursiefen
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: May 22nd 2012 European Ophthalmic Review, 2012;6(3):190 –3 DOI: http://doi.org/10.17925/EOR.2012.06.03.190
Select a Section…
1

Abstract

Overview

Angiogenesis is a complex process that is vital to health but is also a driving factor behind a broad range of malignant, ischaemic, inflammatory, infectious and immune disorders. For optimal efficacy and safety, therapies aimed at preventing angiogenic-mediated disorders must differentiate between healthy and pathological angiogenesis or neovascularisation. Aganirsen is an antisense oligonucleotide that inhibits the insulin receptor substrate (IRS)-1 angiogenic pathway by targeting the IRS-1 messenger RNA. To date, studies of aganirsen have focused mainly on ocular disorders because of the ability to assess non-invasively the effect of the drug on neovascularisation and to address the unmet need for effective therapies in these blinding disorders. Aganirsen (GS-101) eye drops inhibit progressive corneal neovascularisation and appear to be well tolerated. The drug may offer an alternative and/or adjunct to intraocular anti-vascular endothelial cell growth factor (VEGF) agents, which are the current reference standards to prevent neovascularisation in retinal diseases. This is because it has a different and potentially complementary mechanism of action and can be administered topically. Antisense oligonucleotides targeting IRS-1 may present a valuable new approach to control pathological angiogenesis in the eye and elsewhere.

Keywords

Aganirsen (GS-101), antisense oligonucleotide, insulin receptor substrate-1, ocular disorders, topical anti-angiogenic therapy, adjunct to anti-VEGF, healthy and pathological angiogenesis

2

Article

Angiogenesis and its Importance in Health and Disease
The formation of new blood vessels, commonly called ‘angiogenesis’, comprises several processes that include vasculogenesis, where stem cells or angioblasts differentiate into blood vessels and which occurs in developing, initially avascular embryos and to a certain extent in adults;1 and angiogenesis per se, where new blood vessels (especially capillaries) grow from pre-existing vessels by sprouting or branching2 and which is the prevailing mechanism in adults.3

Angiogenesis is necessary to supply tissues with nutrients and oxygen, and is an integral mechanism in many physiological processes, such as wound healing and tissue growth and repair,4 muscle development5 and ovulation.6 At the same time, disruption of the fine balance between factors that induce blood vessel formation and those that inhibit or halt the process can result in pathological angiogenesis, or neovascularisation, leading to increased formation of blood vessels that may be excessive or occur in normally avascular tissue. For example, rapid and persistent growth of new blood vessels is a hallmark of cancer, while excessive angiogenesis can provide a route of entry for inflammatory cells into sites of chronic injury (e.g. Crohn’s disease), contributes to the increased epithelial cell turnover and skin plaques in psoriasis and causes ocular diseases that can lead to blindess.7 Neovascularisation is implicated in a multitude of malignant, ischaemic, inflammatory, infectious and immune disorders.3

As angiogenesis is so vital for health, any therapeutic strategy aimed at treating angiogenic-mediated disease must discriminate between physiological and pathological angiogenesis to ensure that only neovascularisation is affected. It is also important to recognise that all angiogenic mechanisms may participate in neovascularisation to various extents in different diseases. A thorough understanding of the processes controlling angiogenesis and gaining access to as many molecular targets in the relevant regulatory pathways as possible is essential in developing an appropriate therapy.

To view the full article in PDF or eBook formats, please click on the icons above.

2

References

  1. Persson AB, Buschmann IR, Vascular growth in health and
    disease, Front Mol Neurosci, 2011;4:14.

  2. Patan S, Vasculogenesis and angiogenesis, Cancer Treat Res,
    2004;117:3–32.

  3. Carmeliet P, Mechanisms of angiogenesis and arteriogenesis,
    Nat Med, 2000;6(4):389–95.

  4. Li WW, Talcott KE, Zhai AW, et al., The role of therapeutic
    angiogenesis in tissue repair and regeneration,
    Adv Skin Wound Care, 2005;18:491–500.

  5. Gustafsson T, Kraus WE, Exercise-induced angiogenesisrelated
    growth and transcription factors in skeletal muscle,
    and their modification in muscle pathology, Front Biosci,
    2001;1(6):D75–89.

  6. Plendl J, Angiogenesis and vascular regression in the ovary,
    Anat Histol Embryol, 2000;29(5):257–66.

  7. Polverini PJ, Angiogenesis in health and disease: insights into
    basic mechanisms and therapeutic opportunites, J Dent Educ,
    2002;66(8):962–75.

  8. Qazi Y, Maddula S, Ambati BK, Mediators of ocular
    angiogenesis, J Genet, 2009;88(4):495–515.

  9. Bachmann B, Taylor RS, Cursiefen C, The association
    between corneal neovascularization and visual acuity: a
    systematic review, Acta Ophthalmol, 2011
    (Epub ahead of print).

  10. Cursiefen C, Colin J, Dana R, et al., Consensus statement on
    indications for anti-angiogenic therapy in the management of
    corneal diseases associated with neovascularisation:
    outcome of an expert roundtable, Br J Ophthalmol,
    2012;96(1):3–9.

  11. Bressler NM, Early detection and treatment of neovascular
    age-related macular degeneration, J Am Board Fam Pract,
    2002;15(2):142–52.

  12. Bockelbrink A, Roll S, Ruether K, et al., Cataract surgery and
    the development or progression of age-related macular
    degeneration: a systematic review, Surv Ophthamol,
    2008;53(4):359–67.

  13. Kempen JH, O’Colmain BJ, Leske MC, et al., The prevalence
    of diabetic retinopathy among adults in the United States,
    Arch Ophthalmol, 2004;122:552–63.

  14. Shazly TA, Latina MA, Neovascular glaucoma: etiology,
    diagnosis and prognosis, Semin Ophthalmol, 2009;24(2):113–21.

  15. Naumann GOH, General Opühthalmic Pathology. In:
    Naumann GOH, Holbach L, Kruse FE, Applied pathology for
    ophthalmic microsurgeons, Berlin: Springer, 2008;7–28.

  16. Setlur VJ, Parikh JG, Rao NA, Changing causes of enucleation
    over the past 60 years, Graefes Arch Clin Exp Ophthalmol,
    2010;248(4):593–7.

  17. Gergely K, Gerinec A, Retinopathy of prematurity –
    epidemics, incidence, prevalence, blindness, Bratisl Lek Listy,
    2010;111(9):514–7.

  18. Zin A, The increasing problem of retinopathy of prematurity,
    Community Eye Health, 2001;14(40):58–9.

  19. Panda A, Vanthi M, Kumar A, et al., Corneal graft rejection,
    Surv Ophthamol, 2007;52(4):375–95.

  20. Sellami D, Abid S, Bouaouaja G, et al., Epidemiology and risk
    factors for corneal graft rejection, Transplant Proc,
    2007;39:2609–11.

  21. Bachmann B, Taylor RS, Cursiefen C, Corneal
    neovascularization as a risk factor for graft failure and
    rejection after keratoplasty: an evidence-based
    meta-analysis, Ophthalmology, 2010;117(7):1300–5.

  22. Williams KA, Esterman AJ, Bartlett C, et al., How effective is
    penetrating corneal transplantation? Factors influencing
    long-term outcome in multivariate analysis, Transplantation,
    2006;81(6):896–901.

  23. Eye Bank Association of America, Frequently asked
    questions. Available at: www.restoresight.org/aboutus/
    frequently-asked-questions/ (accessed 2 June 2012).

  24. Mitchell P, A systematic review of the efficacy and safety
    outcomes of anti-VEGF agents used for treating neovascular
    age-related macular degeneration: comparison of
    ranibizumab and bevacizumab, Curr Med Res Opin,
    2011;27(7):1465–75.

  25. Kimoto K, Kubota T, Anti-VEGF agents for ocular
    angiogenesis and vascular permeability, J Ophthalmol,
    2012,2012:852183.

  26. Lichtlen P, Lam TT, Nork TM, et al., Relative contribution of
    VEGF and TNF-alpha in the cynomolgus laser-induced CNV
    model: comparing the efficacy of bevacizumab, adalimumab,
    and ESBA105, Invest Ophthalmol Vis Sci, 2010;51(9):4738–45.

  27. Tolentino M, Systemic and ocular safety of intravitreal
    anti-VEGF therapies for ocular neovascular disease,
    Surv Ophthamol, 2011;56(2):95–113.

  28. Saint-Geniez M, Maharaj AS, Walshe TE, et al., Endogenous
    VEGF is required for visual function: evidence for a survival
    role on müller cells and photoreceptors, PLoS One,
    2008;3(11):e3554.

  29. Al-Mahmood S, Colin S, Farhat N, et al., Potent in vivo
    antiangiogenic effects of GS-101 (5-
    TATCCGGAGGGCTCGCCATGCTGCT-3), an antisense
    oligonucleotide preventing the expression of insulin receptor
    substrate-1, J Pharmacol Exp Ther, 2009;329:496–504.

  30. Cloutier F, Lawrence M, Goody R, et al., Antiangiogenic
    activity of aganirsen in nonhuman primate and rodent
    models of retinal neovascular disease after topical
    administration, Invest Ophthalmol Vis Sci, 2012;53(3):1195–203.

  31. Schellekens H, The immunogenicity of therapeutic proteins,
    Discov Med, 2010;9(49):560–4.

  32. Andrieu-Soler C, Berdugo M, Doat M, et al., Downregulation
    of IRS-1 expression causes inhibition of corneal
    angiogenesis, Invest Ophthalmol Vis Sci, 2005;46:4072–8.

  33. Hos D, Regenfuss B, Bock F, et al., Blockade of insulin
    receptor substrate-1 inhibits corneal lymphangiogenesis,
    Invest Ophthalmol Vis Sci, 2011;52:5778–85.

  34. Cursiefen C, Bock F, Horn FK, et al., GS-101 antisense
    oligonucleotide eye drops inhibit corneal neovascularization:
    interim results of a randomized phase II trial, Ophthalmology,
    2009;116:1630–7.

3

Article Information

Disclosure

James W Bainbridge is a NIHR Research Professor and is supported by the NIHR Biomedical Research Centre for Ophthalmology at Moorfields and UCL. He has participated in one clinical trial workshop sponsored by Gene Signal. Claus Cursiefen and Vanya Loroch are consultants to Gene Signal. Eric Viaud is the Chief Executive Officer of Gene Signal International SA.

Correspondence

Claus Cursiefen, University of Cologne, Albertus-Magnus-Platz 1, 50931 Cologne, Germany. E: claus.cursiefen@uk-koeln.de

Support

The publication of this article was funded by Gene Signal.

Received

2012-06-15T00:00:00

4

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
2 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Foreword: touchREVIEWS in Ophthalmology, Volume 17, Issue 2, 2023

Welcome to the latest edition of touchREVIEWS in Ophthalmology, and my first as the journal’s Editor-in-Chief. In this issue, we are delighted to present a series of compelling articles providing insights into some of the cutting-edge developments in this diverse and ever-evolving field. Dhanashree Ratra and Aashna Ratra open the edition with the first in […]

European Ophthalmic Review, 2012;6(3):190 –3 DOI: http://doi.org/10.17925/EOR.2012.06.03.190
Advertisement
    • 5

    Related Content in Retina/Vitreous

    Latest articles videos and clinical updates - straight to your inbox

    Close Popup